Targeting Smoothened Sensitizes Gastric Cancer to Chemotherapy in Experimental Models

Med Sci Monit. 2017 Mar 28:23:1493-1500. doi: 10.12659/msm.903012.

Abstract

BACKGROUND The Hedgehog pathway receptor smoothened (SMO) has critical roles in tumor progression. However, whether SMO is a key factor regulating gastric cancer chemotherapy resistance is unknown. MATERIAL AND METHODS We investigated the potential functions of SMO in inducing gastric cancer paclitaxel resistance in clinical samples, gastric cancer cell lines (424GC and AGS), and subcutaneous syngeneic mouse models. RESULTS We found high SMO expression in paclitaxel-resistant gastric cancer clinical samples. Paclitaxel gastric cancer cells had higher SMO expression than in drug-sensitive cells. Upregulating SMO expression induced paclitaxel resistance in gastric cells lines via enhancing cell proliferation and inhibiting apoptosis. The combination of IPI-926, an inhibitor of SMO, with paclitaxel decreased cell viability of paclitaxel-resistant gastric cancer cells in vitro and controlled tumor growth in animal models. CONCLUSIONS The Hedgehog pathway receptor SMO is an important regulator of gastric cancer paclitaxel resistance and could be a target for sensitizing paclitaxel-resistant tumors.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Mice, Inbred C57BL
  • Paclitaxel
  • Smoothened Receptor / metabolism*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / metabolism*

Substances

  • SMO protein, human
  • Smo protein, mouse
  • Smoothened Receptor
  • Paclitaxel